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Background: Recently, leucine-rich repeats and immunoglobulin-like domains 1 (LRIG1), a negative regulator of
EGFR, was discovered is a novel agent for suppressing bladder cancer. The aim of this study was to investigate the
impact of LRIG1 on the biological features of aggressive bladder cancer cells and the possible mechanisms of
enhanced apoptosis induced by upregulation of LRIG1.
Methods: In this study, we examined the mRNA and protein expression of LRIG1 and EGFR in bladder cancers and
normal bladder. Meanwhile, we overexpressed LRIG1 with adenovirus vector in T24/5637 bladder cancer cell lines,
and we used real time-PCR, western blot, and co-immunoprecipitation analysis in order to examine the effects of
LRIG1 gene on EGFR. Furthermore, we evaluate the impact of LRIG1 gene on the function of human bladder cancer
cells and EGFR signaling.
Results: The expression of LRIG1 was decreased, while the expression of EGFR was increased in the majority of
bladder cancer, and the ratio of EGFR/LRIG1 was increased in tumors versus normal tissue. We found that
upregulation of LRIG1 induced cell apoptosis and cell growth inhibition, and further reversed invasion in bladder
cancer cell lines in vitro by inhibiting phosphorylation of downstream MAPK and AKT signaling pathway.
Conclusion: Taken together, our findings provide us with an insight into LRIG1 function, and we conclude that
LRIG1 evolved in bladder cancer as a rare feedback negative attenuator of EGFR, thus could offer a novel
therapeutic target to treat patients with bladder cancer.
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Bladder cancer is the fourth most common cancer in men
after prostate, lung, and colorectal cancers, accounting for
7% of all cancer case [1]. The majority of bladder tumors
(75%) are non muscle-invasive at diagnosis and after local
surgical therapy, have a high risk of recurrence and a pro-
pensity to progress in grade or stage [2]. At present, its major
treatment is surgical removal but, with surgical approach, re-
currence tends to take place. Muscle invasive tumors (25%)
have a poorer prognosis [3] since 50% of patients will relapse
with metastatic disease within 2 years of treatment. Patients
presenting with muscle invasive cancer or progressing to this* Correspondence: xuhuawhu@163.com
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reproduction in any medium, provided the orstage have a poor survival rate, despite receiving conven-
tional therapies [4]. With the development of the molecular
biology, genes involved in tumorigenesis have been targeted
for the treatment of tumor.
Epidermal growth factor receptor(EGFR) is a trans-
membrane protein tyrosine kinase and over-expressed or
activated in a variety of malignant lesions, including
bladder cancer [5]. Over-expressed or activated EGFR
signaling is the initial step of a cascade of events leading
to tumor cell proliferation, invasion, migration and eva-
sion of apoptosis [6,7]. Inhibition of EGFR by different
approaches causes increased apoptosis and sensitizes
tumor cells to radiation therapy and chemical therapy
[8,9]. Owing to the important role of the EGFR activa-
tion in bladder cancer growth and progression, there-
fore, it is a potential target for molecular therapy for
invasive bladder cancer.Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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alogous genes, namely LRIG1 (formerly LIG1) [10],
LRIG2 [11] and LRIG3 [12]. Leucine-rich repeats and
immunoglobulin-like domains 1(LRIG1) is a transmen-
brane leucine-rich repeat and immunoglobulin(Ig)-like
domain-containing protein, whose transcript is located
at chromosome 3p14.3, a region frequently deleted in
various types of human cancers [10]. It is capable of
interacting with EGFR and enhancing both its basal
and ligand-stimulated ubiquitination and degradation
[13,14]. These reports suggest that LRIG1 is a candidate
suppressor of EGFR activity. Previous studies showed that
upregulation of LRIG1 expression in the superficial blad-
der cancer BIU-87 cell lines resulted in inhibition of cell
proliferation and attenuation of cell invasive abilities, and
played a tumor-suppressive role in vivo in bladder cancer
[15,16]. But the impact of LRIG1 on the biological be-
haviors of aggressive bladder cancer cells in vitro and the
possible mechanisms of enhanced apoptosis induced by
upregulation of LRIG1 is not very clear.
In this study, we observed that LRIG1 expression
appeared significantly downregulated, but EGFR markly
elevated in the majority of bladder cancer compared to
human normal bladder tissue. Upregulation of LRIG1,
followed by a decrease of EGFR on protein expression,
induces cell apoptosis and cell growth inhibition, further re-
versing invasion in aggressive bladder cell lines. Finally, we
demonstrated the capacity of upregulation of LRIG1 to in-
hibit downstream EGFR signaling in bladder cancer cells as
manifested by markedly decreased expression of p-MAPK
and p-AKT. Taken together, we conclude that restoration
of LRIG1 to bladder cancer could offer a novel therapeutic
strategy for suppression of receptor-positive bladder cancer.
Materials and methods
Tissue samples
All of the tissue specimens were obtained between
November 2011 and September 2012 from 50 patients
who underwent surgery for therapeutic treatment at
Tongji Hospital. Immediately after the surgery, samples
were snap-frozen in liquid nitrogen and stored at −80°C.
There were 45 bladder cancer and 5 normal bladder tis-
sues in all of the specimens. As controls, biopsies of nor-
mal bladder samples were obtained from 5 patients who
underwent transvesical prostatectomy. No treatment was
given to the patients before surgery. The samples were
sectioned for hematoxylin and eosin (H&E) staining for
histological confirmation by the Department of Pathology
of Tongji hospital. Tumor staging was determined accord-
ing to the sixth edition of the tumor node metastasis
(TNM) classification of the International Union Against
Cancer. This study was approved by the ethnics commit-
tee of Huazhong University of Science and Technology.
All patients provided informed consent.Reagents and cell culture
The plasmid p3XFLAG-CMV9-LRIG1 and rabbit anti-
human LRIG1 polyclonal antibodies were generous
gifts from Hakan Hedman (Umea University, Sweden).
Two human aggressive bladder cancer cell lines(T24
and 5637) were used in this study. All of this cell lines
were obtained from the American Type Cell Collection
(ATCC), and grown in complete growth medium sup-
plemented with 10% fetal bovine serum(FBS) and main-
tained in a humidified 5% CO2 atmosphere 37°C.
Cell transfection
The plasmid p3XFLAG-CMV9-LRIG1 was transfected into
the two bladder cancer cells by using Lipofectamine2000
reagent (Invitrogen, Groningen, the Netherlands) according
to the manufacturer’s instructions. For control experiments,
the vector p3XFLAG-CMV9-EGFP was also transfected
into the two bladder cancer cells. All transfected cells were
exposed to G418 (800 μg/mL, Sigma Chemical Co., St.
Louis, USA) for 3 weeks of selection. Resistant clones
representing stably transfected cells were ring-cloned and
expanded for further experiment.
siRNAs against EGFR were transfected into T24 and
5637 cells according to the transfection protocol of
Lipofectamine2000 (Invitrogen). A nonspecific control
siRNA strand was used as a negative control. Seventy-
two hours after transfection, knockdown was assessed by
western blot from a parallel transfection. After downreg-
ulation of EGFR, we detected the effect of LRIG1 cDNA
on cell proliferation and EGFR signaling pathway by
CCK-8 assays and western blot respectively.
Quantitative real-time RT-PCR
Total RNA was extracted from 45 cases of bladder cancer
and 5 cases of respective non-neoplastic tissue samples
and 2 bladder cancer cell lines with Trizol reagent. The
expression of LIG1 and EGFR mRNA was done using
quantitative real-time RT-PCR. RNA samples were run in
triplicate using 20 ng of RNA perreaction. The resulting
cDNA samples were amplified by real-time PCR using
gene-specific primer sets in conjunction with the SYBR
Premix Ex Taq (TaKaRa) in a Mx3000p instrument. The
qPCR was performed with the following conditions: acti-
vation at 95°C for 5 min followed by 40 cycles of denatur-
ation at 94°C for 15 s, amplification at 60°C for 30 s,
elongation at 72°C for 30 s. In the last, a cycle of solubility
curve was added to examine the amplification quality. Ex-
pression of mRNA for GAPDH was used as an internal
standard. Reverse transcription products were amplified
by PCR using specific primers for human LRIG1 (forward
5′-GGTGAGCCTGGCCTTATGTGAATA-3′; reverse 5′-
GGTGAGCCTGGCCT TATGTGAATA-3′) and human
EGFR (forward 5′-TCCCTCAGCCACCCATAT GTAC-
3′; reverse 5′-TCCCTCAGCCACCCATATGTAC-3′).
Chang et al. Journal of Experimental & Clinical Cancer Research 2013, 32:101 Page 3 of 9
http://www.jeccr.com/content/32/1/101Immunohistochemistry(IHC)
Formalin-fixed and paraffin-embedded tissue sections
(5 mm) were dewaxed with xylene and rehydrated through
an ethanol gradient into water. Following blocking of en-
dogenous peroxidase activity with 0.3% hydrogen peroxide
for 10 min, the sections were washed with phosphate buff-
ered saline(PBS) and incubated over-night with rabbit
LRIG1 antibody or EGFR antibody at the dilution of 1:100
in a humidified chamber at 4°C. After washing with PBS,
sections were incubated with biotinylated secondary
antibody for 30 min at 37°C and then with horseradish
peroxidase labeled streptavidin for 30 min at 37°C. Diami-
nobenzidine(DAB) was used as chromogen and the sec-
tions were subsequently counterstained with hematoxylin,
then dehydrated, cleared and mounted.
Western blotting analysis
The transfected bladder cancer cells were collected and
washed with 0.01 mol/L PBS for three times. Then the
cells were added into 200ul pre-cold RIPA-PICT cell dis-
ruption liquor and centrifuged. All subsequent manipu-
lations were performed on ice. After centrifugation, the
supernatant was collected. The protein concentration of
each sample was measured with micro-BCA protein
assay reagent. The mixture was heated to 100°C for
5 min to denature the proteins. The protein from each
sample was subjected to electrophoresis on 10% sodium
dodecyl sulfate–polyacrylamide gel. Then protein was
transferred to nitrocellulose membrane, which were
blocked with PBS containing 5% non-fat milk for 2 h and
then incubated with anti-LRIG1 (1:5,000), anti-EGFR
(1:2,000), anti-p-EGFR(1:2,000), anti-MAPK(1:2,000), anti-
p-MAPK(1:2,000), anti-AKT(1:2,000), anti-p-AKT(1:2,000),
anti-caspase-8(1:1,000), anti-MMP-2(1:2,000), anti-MMP-9
(1:2,000) and β-actin(1:2,000) at 4°C overnight. Then sec-
ondary antibody labeled with alkaline phosphatase were
added at room temperature. One hour later, the samples
were washed for three times with TBST, and then visualized
using DAB detection system.
Immunoprecipitation
The total protein was prepared using M-PERTM mammalian
protein extraction reagent (Pierce). For each sample, 10 μL of
anti-LRIG1 antibody or control IgG was added to 1 mg of
protein in 200 μL of lysis buffer and placed on a rocker over-
night at 4°C. Twelve microliters of protein G beads was added
to each sample, which was placed on a rocker at 4°C for 1 h.
The beads were washed three times with 1 ml of lysis buffer
and then boiled in 50 μL of SDS sample buffer; 20 μL was
then loaded per lane and subjected to Western blotting.
Apoptosis analysis
Annexin V-PE/7-aad double staining assay was used to
detect cell apoptosis. After transfected and incubated for3 days, cells were collected, centrifuged and washed with
phosphate—buffered saline(PBS) for two times. Binding
buffer was then added to each tube and cells were
re-suspended. The cells were incubated with 5 μL of
annexin V-PE and 5 μL of 7-aad for 15 min at room
temperature in the dark. Then, the apoptotic analyses
were done by flow cytometry within one hour.
Survival assay by CCK-8
The growth of T24 and 5637 cells after LRIG1 gene
transfection were evaluated by Cell Counting Kit-8 as-
says. Untreated cells, cells treated with liposome alone
and cells treated with the vector control were used for
comparison. Cell suspensions (at 1 × 103/mL) were
transferred to 96-well plates in triplicate and incubate
for 24, 48 and 72 hours. Subsequently, CCK-8(10 μL)
was added to each well, cells were incubated for an add-
itional 4 h. Then, The values of each well was measured
by microplate reader at 450 nm.
Clonal forming assay
T24 and 5637 cells were infected with LRIG1 cDNA and
cultured for 24 h, then plated in 6-well plates at 200
cells/well. Plates were subsequently incubated for 14 days
in a humidified incubator at 37°C, and the colonies were
stained with 0.5 ml of 0.0005% crystal violet solution for
1 h and counted by using a microscope. Five random
fields were counted from each sample and average
values presented ± the SD.
Matrigel invasion assays
The in vitro invasive ability of bladder cancer cells was
measured in transwells chambers assay. 100ul matrigel
was put into upper chambers of the transwell insets.
Incubated the inserts at 37°C for 4 h for gelling and then
pretreated with serum-free medium at 37°C for 1 h before
seeding cells at a density of 2 × 104 /ml with 1% FCS. The
lower chambers of the transwells were filled with 600 ul
medium containing 10% FCS. Then the transwell were
incubated at 37°C with 5% CO2 for 24 h to allow cells to
migrate. After that, removed the cells on the upper side by
wiping with cotton swab. Cells that had invaded through
matrigel were fixed in paraformaldehyde and crystal violet
stained according to the manufacture’s instruction. Cells
that had invaded the matrigel and reached the lower sur-
face of the filter were counted under a light microscope at
a magnification of 200×. We chose five fields of vision and
counted the numbers of the invaded cells and the results
from three separate chambers were then averaged. The
experiment was performed in triplicate.
Statistical analysis
The cell culture data from at least three independent ex-
periments were expressed as means ± SD and examined
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Newman–Keuls test. A Pearson’s correlation test was per-
formed to examine the relationship of LRIG1 and EGFR
expression in bladder cancer and non-neoplastic tissues.
All P-values were two-sided, and values less than 0.05
were considered significant. SPSS v16.0 software was used
for all statistical procedures.
Results
Expression of LRIG1 and EGFR mRNA and protein in
bladder cancer and normal tissue
In order to examine the mRNA expression of LRIG1
and EGFR in bladder cancer, 45 tumor RNA samples
and corresponding 5 normal tissues RNA samples were
analyzed by quantitative real-time RT-PCR. Compared
with corresponding nonneoplastic tissue, the expression
of LRIG1 appeared downregulated in all of the tumor
(Figure 1A). Meanwhile, the expression of EGFR was
elevated in all of the tumor compared to the mean in
the respective non-neoplastic tissue (Figure 1A). Next,
expression of LRIG1 and EGFR protein were determinedFigure 1 Expression of LRIG1 and EGFR mRNA and protein in bladder
expression in bladder cancer with different tumor (T) stages and normal bl
B: Immunohistochemical analysis of LRIG1 and EGFR expression in bladderby IHC. IHC staining also demonstrated downregulation
of LRIG1 protein in bladder cancer tissue (Figure 1B).
Then we compared the expression of LRIG1 and EGFR
in different stage. We found that the LRIG1 expression
in T2-T3 stage were significantly lower than that in T1
stage. This phenomenon could indicate that the expres-
sion of LRIG1 were lower in aggressive bladder cancer.
EGFR was negatively regulated by LRIG1 on bladder
cancer cells
The plasmid p3XFLAG-CMV9-LRIG1 was transfected
into T24 and 5637 cells to analyze whether LRIG1 might
be a functional regulator of EGFR. Effects of LRIG1 gene
transfection on EGFR expression in transcription and
translation level were examined by quantitative real-time
RT-PCR and Western blotting method with their re-
spective primer and antibodies. We observed that LRIG1
gene transfection did not have an impact on the en-
dogenous EGFR mRNA level, but upregulation of LRIG1
was followed by a substantial decrease in the protein
level of EGFR (Figure 2B,C). It can be inferred thatcancer and normal bladder tissue. A: LRIG1 and EGFR mRNA
adder tissue. *P < 0.05 vs normal tissue. #P < 0.05 vs T1 stage.
cancer with different tumor (T) stages and normal bladder tissue.
Figure 2 The effect of LRIG1 transfection on expression of EGFR. A: The mRNA expression of LRIG1 was examined by real time-PCR after
transfection. B: The mRNA expression of EGFR was examined by real time-PCR after transfection. C: The protein expression of LRIG1 and EGFR
was examined by western blot after transfection. Upregulation of LRIG1 significantly decreased endogenous EGFR protein. D: Lysates were immu-
noprecipitated with rabbit anti-LRIG1 or control IgG and blotted with antibodies to EGFR or LRIG1 (*P < 0.05).
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tein, but not via transcription regulation.
Because upregulation of LRIG1 only impact the protein
level of EGFR, subsequently a co-immunoprecipitation
method was used to determine whether there was a
physical interaction between LRIG1 and EGFR mole-
cules. We observed that EGFR could be specifically co-
immunoprecipitated with LRIG1, but not with control
IgG, indicating that two proteins are specifically associ-
ated in complex with each other (Figure 2D).
LRIG1 inhibited cell growth in bladder cancer cells
It was reported previously that inhibition of EGFR sig-
naling could induce apoptosis and inhibit growth of
tumor cells [17,18]. We concluded that upregulation of
LRIG1 could induce the same impact.
CCK-8 assay revealed that the proliferation of T24 and
5637 cells transfected with LRIG1 cDNA was remark-
ably decreased, compared to the corresponding vector
control (P < 0.05) (Figure 3A,B). These results were fur-
ther supported by a quantitative clonal forming assay.
Transfection of T24 and 5637 cells with LRIG1 cDNA
could inhibit cell viability, which would lead to a signifi-
cant decrease of the number of colonies compared with
vector and control cells (P < 0.05) (Figure 3C,D).
LRIG1 induced apoptosis and reversed invasion in
bladder cancer cells
The apoptotic effect of LIRG1 on bladder cancer cell
lines was detected through Annexin V-PE/7-aad doublestaining assay (Figure 4A,B). Stained cells were immedi-
ately analyzed by flow cytometry. Results demonstrated
that LRIG1 overexpression has an effect on increasing
apoptosis. With Annexin V-PE staining, early apoptosis
was clearly detectable in the two bladder cancer cells
treated with transfection of LRIG1. Compared to the corre-
sponding vector control, the cell apoptotic rates of LRIG1
were significantly increased in the two cells (P < 0.05).
We next detected whether LRIG1 regulated cell inva-
sion and motility by using the Matrigel in vitro invasion
assay. As shown in Figure 4C,D, LRIG1 cDNA exerted a
profound effect on cell invasion in the two bladder can-
cer cells. Compared with the vector and control cells,
the T24 and 5637 cells transfected with LRIG1 cDNA,
showed a considerably lower invasion potential. These
observations indicated that the enhanced expression of
LRIG1 was associated with reversed invasive ability.
Effect of LRIG1 gene transfection on EGFR signaling
To further demonstrate overexpression of LRIG1 indu-
cing the observed growth inhibition and apoptosis that
might correlate with downstream EGFR signaling, we
examined the effect of LRIG1 gene transfection on the
expression of several key regulators involved in the EGFR
signaling pathway. As shown in Figure 5A, western blot
analysis detected that upregulation of LRIG1 resulted in a
significant reduction in phosphorylation of EGFR (p-EGFR)
and EGFR in T24 and 5637 cells. The level of activated
mitogen-activated protein kinase (p-MAPK), a downstream
regulator of EGFR signaling, showed remarkable decrease
Figure 3 Effect of LRIG1 gene transfection on growth of human bladder cancer cells. A: LRIG1 gene transfection could inhibit T24
proliferation by cck-8 assay(*P < 0.05). B:LRIG1 gene transfection could inhibit 5637 proliferation by cck-8 assay (*P < 0.05). C: LRIG1 gene transfec-
tion could inhibit cell viability by quantitative clonal forming assay. D: Data showed transfection of LRIG1 cDNA could significantly inhibit the cell
viability as compared with vector cells (*P < 0.05). All experiments were repeated at least three times.
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p-AKT expression was also observed with LRIG1 cDNA
transfection, compared with the vector control.
Caspases represent central regulators of apoptosis. we
examined the levels of the active form of caspase-8 to
detect the apoptotic response. As shown in Figure 5B,
compared with the vector control, the expression of ac-
tive (cleaved) caspase-8 in the two bladder cancer cells
was significantly increased treated with LRIG1 gene. We
next measured the level of MMP-2 and MMP-9 in this
two bladder cancer cells. Treatment with LRIG1 cDNA
caused a significant decrease in MMP-2 and MMP-9
Which involved in reversed invasion induced by LRIG1.
Effect of EGFR knockdown on LRIG1-induced cell
proliferation and signal pathway regulation
To determine whether EGFR expression is critical for
the effect of LRIG1 on bladder cancer cells in vitro, we
next used specific genetic inhibition of EGFR to assess
the consequences of its inhibition on LRIG1 mediated cell
proliferation and signal pathway regulation. First, we con-
firmed that the EGFR siRNA effectively reduced the EGFR
protein level in T24 and 5637 cells (Figure 6A). Then we
found EGFR knockdown significantly decreased the effect
of LRIG1 cDNA on cell proliferation compared withcontrol-siRNA-transfected cells (Figure 6B). And EGFR
siRNA significantly weakened the effect of LRIG1
cDNA on the EGFR signaling pathway regulation in
both cell lines compared with cells transfected with
control siRNA (Figure 6C).
Discussion
Kekkon proteins negatively regulate the epidermal growth
factor receptor (EGFR) during oogenesis in Drosophila.
Their structural relative in mammals, LRIG1, is a trans-
membrane protein, could restrict growth factor signaling
by enhancing receptor ubiquitylation and degradation
[13]. The feasibility and efficacy of the inhibitory effects of
LRIG1 on tumor through inhibiting EGFR signaling activ-
ity have been studied in renal cancer, glioma, squamous
cell carcinoma of skin, colorectal cancer and prostate
cancer [19-23]. In this study, we attempted to evaluate the
inhibitory effects of LRIG1 on aggressive bladder cancer
cells.
EGFR is a well-studied, versatile signal transducer that
is overexpressed in many types of tumour cells, including
lung, colon and prostatic carcinoma, and up-regulation of
EGFR is associated with poor clinical prognosis [24,25].
EGFR is a 170 kDa tyrosine kinase receptor consisting of
an extracellular ligand-binding domain, a transmembrane
Figure 4 LRIG1 gene transfection induced apoptosis and inhibit invasion in bladder cancer cells. A: LRIG1 gene transfection induced
apoptosis in human T24 and 5637 cell lines by flow cytometry analysis. B: The percentages are displyed showing the annexin V positive/7-aad
negative fraction. Columns are expressed as mean ± SD of three independent experiments. *P < 0.01 for LRIG1 cDNA versus vector. C: Effect of
LRIG1 gene transfection 24 h on the cell invasion of human bladder cancer cells. D: Data showed transfection of LRIG1 cDNA could significantly
inhibit the cell invasion as compared with vector cells (*P < 0.05). All experiments were repeated at least three times.
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domain and the C-terminus region with multiple tyrosine
residues [26]. EGFR mediates signals that stimulate prolif-
eration, migration, and metastasis in many tumour types
[25,27], and its signal transduction is regulated by stimula-
tory and inhibitory inputs. LRIG1, whose extracellular
region was organized with leucine-rich repeats (LRRs) andFigure 5 Effect of LRIG1 gene transfection on protein expression of s
caspase-8, MMP-2 and MMP-9 (B) of T24 and 5637 cells.immunoglobulin-like domains homologous to mammalian
decorin and the Drosophila Kekkon-1 gene, antagonizes
the activity of epidermal growth factor receptor family
receptor tyrosine kinases and acts within a framework of a
negative feedback loop [28]. In our study, we found that
the expression of LRIG1 was decreased, whereas the
expression of EGFR was increased in bladder cancer tumoreveral key regulators involved in the EGFR signaling pathway (A),
Figure 6 Effect of EGFR knockdown on LRIG1-induced cell proliferation and signal pathway regulation. A: Genetic suppression of EGFR
by EGFR-siRNA transfection. B: Proliferation of cells treated with LRIG1 cDNA after transfection with EGFR siRNA or control siRNA. *P < 0.05 vs cells
transfected with control siRNA. C: Effects of silencing EGFR on the LRIG1-induced regulation of the expression of AKT, MAPK, and their
phosphorylated forms.
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downregulation of the LRIG1 gene may be involved in the
development and progression of the bladder cancer.
In order to detect the relationship between LRIG1 and
EGFR on bladder cancer cells, we examined the expres-
sion level of EGFR on T24 and 5637 cells after transfec-
tion of LRIG1 cDNA. We observed that up-regulation of
LRIG1 did not have an impact on the endogenous EGFR
mRNA level, but it was followed by a substantial de-
crease in the protein level of EGFR. It was reported that
upregulation of LRIG1 transcript and protein upon EGF
stimulation, and physical association of the encoded pro-
tein with the four EGFR orthologs of mammals [13]. As
we known, LIRG1 could enhance the ligand stimulated
ubiquitination of ErbB receptors in a c-Cbl dependent
manner [14]. Cbl-mediated receptor ubiquitylation marks
the onset of attenuation. The previous study indicates that
overexpression of Cbl in cells promotes EGF-stimulated
receptor ubiquitylation and degradation [29].
In the following study, we concluded that upregulation
of LRIG1 could induce cell apoptosis and suppress cellgrowth, and furthermore reverse cell invasion in T24
and 5637 cells. All of this changes of biological behavior
suggest that LRIG1 is a tumor suppressor gene on ag-
gressive bladder cancer cells. However, the change of
biological behavior is not exclusively attributed to the
restriction of one molecule, as the signal transduction is
a complicated matter in cells [21,30]. In our study, we
examined the effect of LRIG1 gene transfection on the
expression of several key regulators involved in the
EGFR signaling pathway, including MAPK and AKT.
We found that p-MAPK and p-AKT in T24 and 5637
cells were significantly reduced following LRIG1 cDNA
transfection which also inhibited phosphorylation of
EGFR. Because of the above results we can conclude
that LRIG1 indeed affects the biology behaviors of bald-
der cancer cells in vitro by inhibiting phosphorylation of
EGFR and the downstream signaling pathway. And we
found that EGFR expression is critical for the effect of
LRIG1 on bladder cancer cells in vitro. Taken together,
these results could offer a novel therapeutic strategy for
suppression of bladder cancer by restoration of LRIG1.
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